NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics
Open Access
- 2 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 23 (1) , 63-75
Abstract
Background: Intracarotid injection of mannitol has been applied for decades to support brain entry of therapeutics that otherwise do not effectively cross the blood–brain barrier (BBB). However, the elaborate and high-risk nature of this procedure has kept its use restricted to well-equipped medical centers. We are developing a more straightforward approach to safely open the BBB, based on the intra-arterial (IA) injection of NEO100, a highly purified version of the natural monoterpene perillyl alcohol. Methods: In vitro barrier permeability with NEO100 was evaluated by transepithelial/transendothelial electrical resistance and antibody diffusion assays. Its mechanism of action was studied by western blot, microarray analysis, and electron microscopy. In mouse models, we performed ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan’s blue, methotrexate, checkpoint-inhibitory antibodies, or chimeric antigen receptor (CAR) T cells. Results: NEO100 opened the BBB in a reversible and nontoxic fashion in vitro and in vivo. It enabled greatly increased brain entry of all tested therapeutics and was well tolerated by animals. Mechanistic studies revealed effects of NEO100 on different BBB transport pathways, along with translocation of tight junction proteins from the membrane to the cytoplasm in brain endothelial cells. Conclusion: We envision that this procedure can be translated to patients in the form of transfemoral arterial catheterization and cannulation to the cerebral arteries, which represents a low-risk procedure commonly used in a variety of clinical settings. Combined with NEO100, it is expected to provide a safe, widely available approach to enhance brain entry of any therapeutic.Keywords
Funding Information
- NeOnc Technologies, Inc
- USC Wright Foundation
- National Institutes of Health
- National Cancer Institute (1R41CA217551)
- Sharyl and Oscar Garza Research Fund
This publication has 23 references indexed in Scilit:
- Perillyl Alcohol for the Treatment of Temozolomide-Resistant GliomasMolecular Cancer Therapeutics, 2012
- Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapyJournal of Neuro-Oncology, 2010
- Review: Chemotherapy in newly diagnosed primary central nervous system lymphomaTherapeutic Advances in Medical Oncology, 2010
- Glioma-associated endothelial cells are chemoresistant to temozolomideJournal of Neuro-Oncology, 2009
- The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunctionSeminars in Immunopathology, 2009
- Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomasSurgical Neurology, 2008
- High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinionsLeukemia & Lymphoma, 2008
- Seizure‐Promoting Effect of Blood–Brain Barrier DisruptionEpilepsia, 2007
- Selective Enrichment of Membrane Proteins by Partition Phase Separation for Proteomic StudiesBioMed Research International, 2003
- Cytotoxicity and Biotransformation of the Anticancer Drug Perillyl Alcohol in PC12 Cells and in the RatToxicology and Applied Pharmacology, 2000